[{"id":"b5311e32-e5a1-4a67-a74a-af139d0dfb7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04958811","created_at":"2021-07-12T15:53:06.793Z","updated_at":"2025-02-25T16:38:29.835Z","phase":"Phase 2","brief_title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","source_id_and_acronym":"NCT04958811","lead_sponsor":"Georgetown University","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK wild-type • ROS1 wild-type","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-06"},{"id":"f13bc4e9-84c6-44f1-8827-fcfe07499b5c","acronym":"PRIME_LUNG","url":"https://clinicaltrials.gov/study/NCT05222087","created_at":"2022-02-05T18:29:12.695Z","updated_at":"2024-07-02T16:35:14.201Z","phase":"Phase 1","brief_title":"PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study","source_id_and_acronym":"NCT05222087 - PRIME_LUNG","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" EGFR • ROS1","pipe":" | ","alterations":" ALK wild-type • ROS1 wild-type","tags":["EGFR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/03/2022","start_date":" 01/03/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-03-18"},{"id":"04a9b159-8750-41fc-9f7f-22b4395ff6ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05460481","created_at":"2022-07-15T16:05:34.868Z","updated_at":"2024-07-02T16:36:07.086Z","phase":"Phase 2","brief_title":"Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors","source_id_and_acronym":"NCT05460481","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" EGFR • ROS1","pipe":" | ","alterations":" ALK wild-type • ROS1 wild-type","tags":["EGFR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/12/2022","start_date":" 06/12/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-07-20"},{"id":"1bacf18f-4d19-44c7-8a92-f00db536eed3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05055583","created_at":"2021-09-24T14:55:09.853Z","updated_at":"2025-02-25T16:26:42.014Z","phase":"Phase 2","brief_title":"Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC","source_id_and_acronym":"NCT05055583","lead_sponsor":"Tang-Du Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • ALK wild-type • ROS1 wild-type","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-09-24"},{"id":"3221b2ed-59d5-42f8-9362-f16e8b9e7f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03466268","created_at":"2021-01-17T17:53:18.793Z","updated_at":"2024-07-02T16:36:48.917Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety and Anti-tumor Activity of SCC244","source_id_and_acronym":"NCT03466268","lead_sponsor":"Haihe Biopharma Co., Ltd.","biomarkers":" KRAS • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR mutation • MET amplification • MET exon 14 mutation • MET overexpression • ALK mutation • MET mutation • ROS1 wild-type","tags":["KRAS • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • MET exon 14 mutation • MET overexpression • ALK mutation • MET mutation • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Haiyitan (gumarontinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 113","initiation":"Initiation: 09/14/2017","start_date":" 09/14/2017","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2020-03-11"},{"id":"ce3736cc-4e31-45d3-bb0f-4bd380fee0e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03636685","created_at":"2021-01-18T17:51:27.412Z","updated_at":"2024-07-02T16:37:07.770Z","phase":"Phase 1/2","brief_title":"Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC","source_id_and_acronym":"NCT03636685","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Focus V (anlotinib) • pemetrexed"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 08/14/2019","primary_completion_date":" 08/14/2019","study_txt":" Completion: 08/14/2020","study_completion_date":" 08/14/2020","last_update_posted":"2018-08-17"}]